How do you choose between blinatumomab and CAR-T cell therapy for relapsed or refractory pre B- ALL?  

Many of the cellular therapy products are limited in indication which can help with making the decision, as well as the plan to go to transplant or not. Blinatumomab would have to be consolidated with HSCT while CAR-T can be curative in about 50% of patients without consolidative HSCT, which would b...